Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

Arthritic Psoriasis

Tundra lists 2 Arthritic Psoriasis clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07858591

Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study.

In terms of blood flow per unit of tissue, the retina is one of the tissues with the highest blood flow in the body. Parameters such as the thickness of the choroid layer, which plays a crucial role in maintaining normal eye function, the dimensions of the foveal avascular zone (FAZ) supplied by this layer, and retinal vascular networks can be measured using non-invasive methods. OCTA (Optical Coherence Tomography Angiography) is an imaging tool that enables the non-invasive assessment of retinal microvascular densities and the measurement of the foveal avascular zone's dimensions. Studies conducted to date indicate that retinal capillary vessels and the dimensions of the foveal avascular zone are affected in rheumatological diseases, especially associated with systemic inflammation. This study aims to compare retinal capillary vessel density and foveal avascular zone dimensions in patients with psoriatic arthritis against those in a healthy population and in patients with psoriasis who do not have psoriatic arthritis, utilizing the non-invasive method of optical coherence tomography angiography.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-10-13

1 state

Arthritic Psoriasis
Psoriasis (PsO)
Retinal Vessels
NOT YET RECRUITING

NCT07706530

Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)

Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheumatologic Score (ACR) and key secondary outcomes are the change on ACR20% at week 16 and ACR50/70% at week 24. Eligible patients will be randomly assigned (1:1:1) to receive oral CBP-0276 200mg QD, 800mg QD or placebo for CBP-0276 for 24 weeks

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-07-16

1 state

Arthritic Psoriasis